Othomyxo and paramyxoviruses

An introduction to 2 major human viruses : Ortho and Paramyxoviridae emphasizing on their main pathogens.

1. Kaveh Haratian
PhD. Medical Virologist
Department of Microbiology and Immunology
School of Medicine
1

2. A22-yearoldmansuddenlyexperienced
headache,myalgia,malaise,drycough,and
fever.Hebasicallyfelt“lousy”.Afteracouple
ofdays,hehadasorethroat,hiscoughhad
worsened,andhestartedtofeelnauseated
andvomited.Severalofhisfamilymembers
hadexperiencedsimilarsymptomsduringthe
previoustwoweeks.
2

3. Characteristics:
•Influenza A, B and C the only members
•Enveloped virion; inactivated by detergents
•Segmented negative-sense RNA genome
with eight nucleocapsidsegments
•Genetic instability responsible for annual
epidemics (mutation:drift) and periodic
pandemics (reassortment: shift)
3

4. Structure & Replication:
•Envelope with two group-specific glycoproteins:
1.Hemagglutinin(HA)
Functions:
a.Viral attachment protein –bind to sialic
acidon epithelial cell surface
receptors
b.Promotes fusion of the envelope to the
cell membrane
c.Hemagglutinateshuman, chicken and
guinea pig rbc
d.Elicits protective neutralizing antibody
response
4

5. Structure & Replication:
•Envelope with two group-specific glycoproteins:
2.Neuraminidase (NA)
With enzyme activity
Cleaves the sialicacid on glycoproteins,
including the cell receptor prevents
clumping & facilitates release of virus
from infected cells
Target for two antiviral drugs: zanamivir
(Relenza) and oseltamivir(Tamiflu)
5

6. Structure & Replication:
•Type-specific proteins: used to differentiate
among influenza A, B, and C viruses
1.Matrix protein (M
1)
Viral structural protein
Interacts with nucleocapsid& envelope
promotes assembly
2.Membrane protein (M
2)
Forms membrane channel
Facilitates uncoating& HA production
Target for amantadine
3.Nucleocapsidproteins (NP)
6

7. Structure & Replication:
•Transcribes and replicates its genome in the
target cell nucleus
•Assembles and buds from the plasma
membrane
7

8. Pathogenesis & Immunity:
•Virus first targets & kills mucus-secreting, ciliated,
and other epithelial cells loss of primary
defensesystem
•Cleavage of sialicacid residues of mucus by NA 
provide access to tissues
•Preferential release of the virus at the apical
surface of epithelial cells and into the lungs 
promote cell-to-cell spread & transmission to other
hosts
8

9. Pathogenesis & Immunity:
•Spread to lower respiratory tract shedding of
bronchial or alveolar epithelium
•Promotes bacterial adhesion to the epithelial cells
pneumonia
•Histologic: inflammatory response of mucosal
membrane (primarily monocytes& lymphocytes)
with submucosaledema
9

10. Pathogenesis & Immunity:
•Systemic symptoms due to the interferon and
lymphokineresponse to the virus
•Local symptoms due to epithelial cell damage
•Interferon & CMI responses (NK & T cell)
important for immune resolution and
immunopathogenesisclassic symptoms
associated with interferon induction
•Antibody important for future protection against
infection
10

11. Pneumonia Secondary bacterial pneumonia
Primary viral pneumonia
CNS/muscle involvement
Antibody
T-cell
response
Future protection
Interferon
induction
Aerosol
inoculation
of virus
Replication
in resp. tract
Desquamation
of mucus-
secreting and
ciliated cells
Influenza
syndrome
Major contributors to pathogenesis
Immune response
Less frequent outcomes
11

12. Why is influenza difficult to
control even when there is
vaccination available?
12

13. Antigenic Changes:
1.Antigenic drift
•Minor change
•Mutation of the HA and NA genes
•Occurs every 2 to 3 years
•Cause local outbreaks of influenza A & B
2.Antigenic shift
•Major change
•Result from re-assortment of genomes
among different strains, including animal
strains
•Associated with pandemics
•Occurs only with influenza A
13

14. Lung cell
Human
influenza
virus
Chicken
influenza
virus
Re-assortment of RNA
genome segments
New strain of influenza
virus
14

15. How is the virus
transmitted?
15

16. •Virus is spread by inhalation of aerosol
droplets expelled during talking, breathing,
and coughing.
•Virus likes cool, less humid atmosphere
•Virus is extensively spread by school
children.
16

17. Who is at risk?
17

18. Seronegativepeople.
Adults: classic “flu” syndrome
Children: asymptomatic to severe respiratory
tract infection
High-risk Groups:
Elderly
Immunocompromised people
People with underlying cardiac or
respiratory problems (including people
with asthma and smokers)
18

19. What are the clinical
syndromes associated with
the virus? What are the
possible complications?
19

20. Diseases Associated with Influenza Virus Infections
Disorder Symptoms
Acute infection in adultsRapid onsetof fever, malaise, myalgia,
sore throat, and non-productive cough
Acute infection in childrenAcute disease similar to that in adults
but with higher fever, gastrointestinal
tract symptoms (abdominal pain,
vomiting), otitismedia, myositis, and
more frequent croup
Complications Primary viral pneumonia
Secondary bacterial pneumonia
Myositis& cardiac involvement
Neurologic syndromes:
Guillain-Barresyndrome
Encephalopathy
Encephalitis
Reye’s syndrome
20

21. How would the
diagnosis of influenza
be confirmed?
21

22. Laboratory Diagnosis of Influenza Virus Infection
Test Detects
Cell culture
Hemadsorptionto
infected cells
Hemagglutination
Hemagglutinationinhi-
bition
Antibody inhibition of
hemadsorption
Immunofluorescence,
ELISA
Serology: HI, headsorp-
tioninhibition, ELISA,
immunofluorescence,
complement fixation
Presence of virus, limited cytopathologic
effects
Presence of HA protein on cell surface
Presence of virus in secretions
Type and strainof influenza virus or
specificity of antibody
Identification of influenza type and strain
Influenza virus antigens in respiratory
secretions or tissue culture
Seroepidemiology
22

23. Which antiviral drugs are
effective for the treatment of
influenza virus infection? What
are the targets & mechanisms of
action of these drugs?
23

24. Amantadine, Rimantadine
•Target: M2 protein inhibit an uncoating
step
•Do not affect influenza B or C virus
Zanamivir(Relenza) & Oseltamivir(Tamiflu)
•Target: neuraminidase prevent release of
virus from infected cells
•Inhibit both influenza A and B
•Effective for prophylaxis and for treatment
during the first 24 to 48 hours after the
onset of influenza A illness
24

25. What is the best way to
control the virus?
25

26. The best way to control the virus is through
IMMUNIZATION!
•Killed vaccine representing the “strains of the
year”
oKilled (formalin-inactivated) whole-virus
vaccine
oDetergent-treated virionpreparations and
HA-and NA-containing detergent extracts
of virus
•Vaccination routinely recommended for the
elderly and people with chronic pulmonary or
heart disease.
26

27. 27

28. Properties of Orthomyxovirusesand Paramyxoviruses
Property Orthomyxoviruses Paramyxoviruses
Viruses Influenza A, B, and C Measles, mumps,RSV, and
parainfluenzaviruses
Genome Segmented (8 pieces) ssRNA
of negative polarity
Non-segmented ssRNAof
negative polarity
VirionRNA
polymerase
Yes Yes
Capsid Helical Helical
Envelope Yes Yes
Size Smaller (110 nm) Larger (150 nm)
Surface spikes HA and NA on different
spikes
Hemagglutinin&
neuraminidase on same
spikes
Giant cell
formation
No Yes
28

29. Members of the Family Paramyxoviridae
Genus Human pathogens
Morbillivirus
Paramyxovirus
Pneumovirus
Measles virus
Parainfluenzaviruses 1 to 4
Mumps virus
Respiratory syncytialvirus
Nipahvirus (1998, Malaysia and
Singapore)
Hendravirus (1994, Australia)
29

30. Members of the Family Paramyxoviridae
30

31. Unique Features of the Paramyxoviridae
•Large virionwith helical nucleocapsid
•Negative RNA genome
•Envelope containing viral attachment protein (HN,
paramyxovirusand mumps virus; H, measles
virus, and G, RSV) and a fusion protein (F)
oHN with hemagglutinin& neuraminidase activity
oH with hemagglutininactivity
oG without hemagglutininor neuraminidase acvitity
•Replicates in cytoplasm
•Penetrate the cell by fusion with and exit by
budding from the plasma membrane
•Induce cell-to-cell fusion multinucleated giant
cells
31

32. Envelope Spikes of Paramyxoviruses
Virus HemagglutininNeuraminidase Fusion
protein
1
Measles virus + - +
Mumps virus
2
+ + +
Respiratory
syncytialvirus
- - +
Parainfluenza
virus
2
+ + +
1
The measles and mumps fusion proteins are also hemolysins.
2
In mumps and parainfluenzaviruses, the hemagglutininand
neuraminidase are on the same spike and the fusion protein is on a
different spike.
32

33. An18-yearoldcollegefreshman
complainedofacough,runnynose,and
conjunctivitis.Thephysicianinthe
campushealthcenternoticedsmall
whitelesionsinsidethepatient’smouth.
Thenextday,aconfluentredrash
coveredhisfaceandneck.
33

34. •How is the disease
transmitted?
•What clinical characteristics
of this case were diagnostic
for measles?
•When was the patient
contagious?
34

35. 35

36. Transmission:
•Inhalation of large-droplet aerosols
Disease Mechanisms:
•Infect epithelial cells of respiratory tract
•Spread systemically in lymphocytes and
by viremia
•Replicate in cells of conjunctivae,
respiratory tract, lymphatic system,
blood vessels, and CNS
•Characteristic rash caused by immune T
cells targeted to measles-infected
endothelial cells lining small blood
vessels
36

37. Mechanisms of spread and pathogenesis of measles
Inoculation of
respiratory tract
Local replication
in respiratory
tract
Lymphatic
spread
Viremia
Wide
dissemination
Conjunctivae
Respiratory tract
Urinary tract
Small blood vessels
Lymphatic system
CNS
Virus-infected
cell + immune
T cells
RASH
Recovery
(lifelong
immunity)
Post-infectious
encephalitis
(immunopathological;
etiology)
Subacutesclerosing
panencephalitis
(defective measles
virus infection of CNS)
No resolution of acute
infection due to
defective CMI
(frequently fatal
outcome)
37

38. •Incubation period: 7 to 13 days
•Prodrome: high fever + 3C’s + P most infectious
•Koplik’sspots after 2 days of illness last 24 to
48 hours
•Appearance of exanthemwithin 12 to 24 hours of
the appearance of Koplik’sspots
•Rashes undergo brawny desquamation
38

39. 39

40. 40

41. Clinical Consequences of Measles Virus Infection
Disorder Symptoms
Measles Characteristicmaculopapularrash, cough,
conjunctivitis, coryza, photophobia,
Koplik’sspots
Complications: otitismedia, croup,
bronchopneumonia, and encephalitis
Atypical measles Rash (most prominent in distal areas);
possible vesicles, petechiae, purpura,or
urticaria
SSPE CNS manifestations (e.g. Personality,
behavior, and memory changes; myoclonic
jerks; spasticity;and blindness)
41

42. How can the
infection be
prevented?
42

43. Post-exposure: Immune serum globulin given
within six days of exposure
Pre-exposure:
1.Live, attenuated vaccine
2.MMR
•Composition:
a.Measles –Schwartz or Moratensubstrainsof
Edmonton B strain
b.Mumps –JerylLynn strain
c.Rubella –RA/27-3 strain
•Schedule: at 15-24 months and at 4-6 years
•Efficacy: 95% lifelong immunization with a
single dose
43

44. A13-month-oldchildhadarunnynose,
mildcough,andlow-gradefeverforseveral
days.Thecoughgotworseandsounded
like“barking.”Thechildmadeawheezing
soundwhenagitated.Thechildappeared
wellexceptforthecough.Alateral
radiographoftheneckshowedasub-
glotticnarrowing.
44

45. What is the specific and
common name for these
symptoms?
45

46. What other agents would cause
a similar clinical presentation
(differential diagnosis)?
What is the most common
cause?
46

47. How was the virus
transmitted?
Answer: Droplet inhalation
47

48. ParainfluenzaViruses
Characteristics:
•Four serotypes
•Infection limited to upper respiratory tract
Upper respiratory tract disease most
common, but significant disease can occur
with lower respiratory tract infection
•Not systemic and do not cause viremia
•Infection induces protective immunity of short
duration
48

49. ParainfluenzaViruses
Four serologic types
•Types 1, 2, and 3
Second only to RSV as important causes of
severe lower respiratory tract infection in
infants and young children
Cause respiratory tract syndromes ranging
from amild cold-like URTI to bronchiolitisto
pneumonia
Especially associated with croup
•Type 4
Mild upper respiratory tract infection in
children and adults
49

50. ParainfluenzaViruses
•Clinical:
•Main cause of croup in children < 5 y/o
•Characterized by harsh cough (“seal bark
cough” and hoarseness due to subglottal
swelling
•Other clinical conditions: common cold,
pharyngitis, otitismedia, bronchitis, and
pneumonia
50

51. Respiratory SyncytialVirus
•Most important cause of pneumonia and
bronchiolitisin infants
•Fusion protein causes formation of
multinucleated giant cells syncytia
•Humans and chimpanzees are the natural
hosts
•Two serotypes –subgroup A and B
51

52. Respiratory SyncytialVirus
•MOT:
1.Respiratory droplets
2.Direct contact of contaminated hands with the
nose or mouth
•Infection in infants more severe and usually
involves lower respiratory tract than in older
children and adults
•No viremiaoccurs
52

53. Respiratory SyncytialVirus
•Severe disease in infants with
immunopathogenicmechanism
oMaternal antibody passed to infant react with
the virus form immune complexes damage
respiratory tract cells
•Most individuals with multiple infections indicate
incomplete immunity
•IgArespiratory antibody reduces the frequency of
infection as a person ages
53

54. Respiratory SyncytialVirus
•Clinical:
1.Bronchiolitis
2.Pneumonia
3.Otitismedia in young children
4.Croup
5.Upper respiratory tract infection similar to
common cold in older children and adults
54

55. Respiratory SyncytialVirus
•Treatment:
Aerosolized ribavirin(Virazole) for
severely ill hospitalized infants
Combination ribavirin+ hyperimmune
globulin may be more effective
55

56. A7year-oldboydevelopedfever,body
malaise,andlossofappetite.Thiswas
followedbytenderswellingaroundthe
rightmandibulararea,withincreasein
thepaineverytimehedrinkscalamansi
juice.Theconditionspontaneously
resolvedafteroneweek.
56

57. Mumps Virus
•Two types of envelope spikes:
1.With both hemagglutininand neuraminidase
activities
2.With cell-fusing and hemolyticactivities
•Only one serotype
•Neutralizing antibodies directed against the
hemagglutinin
•Humans are natural hosts
57

58. Mumps Virus
•MOT: respiratory droplets
•Infects both upper and lower respiratory
tracts spread through blood parotid
glands, testes, ovaries, pancreas, and in
some cases, meninges
•Occurs only once subsequent cases may
be caused by parainfluenzaviruses,
bacteria, and by duct stones
58

59. Mumps Virus
59

60. Mumps Virus
60

61. Mumps Virus
•Complications:
1.Orchitisin post-pubertal males may lead to
sterility if bilateral
2.Meningitis –usually benign, self-limited, and
without sequelae
61

62. Mumps Virus
•Prevention:
Live, attenuated vaccine given subcutaneously to
children at 15 months of age (MMR)
Immune globulin not useful for preventing or
mitigating mumps orchitis.
62

63. 63